Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IBM Makes Big Health Care Splash With J&J, Medtronic, Apple

This article was originally published in The Gray Sheet

Executive Summary

IBM is partnering with some major medical technology players to use its Watson Health Cloud to aggregate medical data and use cognitive computing to provide physicians and researchers with more treatment options.

You may also be interested in...



IBM Digs Deeper Roots In Medtech, As AdvaMed Builds Digital Footprint

IBM is getting more heavily invested in the medical device industry, announcing two major partnerships this week with diagnostic-maker Illumina and US FDA. The move is part of a larger industry trend of tech firms becoming more active in the medtech sector, and AdvaMed is adjusting to the new context.

Watson, M.D.: How IBM And Cleveland Clinic Are Working To Reboot Health Care With Supercomputing

IBM is working with Cleveland Clinic to bring Watson, the supercomputer “Jeopardy!” winner, to health care to change the way clinical decisions are made.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel